These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 12325163)
1. Inhibition of proteolysis and other posttranslational modifications with substrate-targeted inhibitors. Kodadek T Biopolymers; 2002; 66(2):134-40. PubMed ID: 12325163 [TBL] [Abstract][Full Text] [Related]
2. Designed helical peptides inhibit an intramembrane protease. Das C; Berezovska O; Diehl TS; Genet C; Buldyrev I; Tsai JY; Hyman BT; Wolfe MS J Am Chem Soc; 2003 Oct; 125(39):11794-5. PubMed ID: 14505382 [TBL] [Abstract][Full Text] [Related]
3. Proteases--structures, mechanism and inhibitors. Powers JC; Odake S; Oleksyszyn J; Hori H; Ueda T; Boduszek B; Kam C Agents Actions Suppl; 1993; 42():3-18. PubMed ID: 8356929 [TBL] [Abstract][Full Text] [Related]
4. Evidence of a conformational change in the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl inhibitors. Bonneau PR; Grand-Maître C; Greenwood DJ; Lagacé L; LaPlante SR; Massariol MJ; Ogilvie WW; O'Meara JA; Kawai SH Biochemistry; 1997 Oct; 36(41):12644-52. PubMed ID: 9376371 [TBL] [Abstract][Full Text] [Related]
5. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Tsantrizos YS Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464 [TBL] [Abstract][Full Text] [Related]
6. NMR study of complexes between low molecular mass inhibitors and the West Nile virus NS2B-NS3 protease. Su XC; Ozawa K; Yagi H; Lim SP; Wen D; Ekonomiuk D; Huang D; Keller TH; Sonntag S; Caflisch A; Vasudevan SG; Otting G FEBS J; 2009 Aug; 276(15):4244-55. PubMed ID: 19583774 [TBL] [Abstract][Full Text] [Related]
7. Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations. Rich DH; Bursavich MG; Estiarte MA Biopolymers; 2002; 66(2):115-25. PubMed ID: 12325161 [TBL] [Abstract][Full Text] [Related]
8. Biochemical and molecular characterization of a detergent-stable serine alkaline protease from Bacillus pumilus CBS with high catalytic efficiency. Jaouadi B; Ellouz-Chaabouni S; Rhimi M; Bejar S Biochimie; 2008 Sep; 90(9):1291-305. PubMed ID: 18397761 [TBL] [Abstract][Full Text] [Related]
9. Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing. Fairlie DP; Tyndall JD; Reid RC; Wong AK; Abbenante G; Scanlon MJ; March DR; Bergman DA; Chai CL; Burkett BA J Med Chem; 2000 Apr; 43(7):1271-81. PubMed ID: 10753465 [TBL] [Abstract][Full Text] [Related]
10. Modeling the binding affinities of beta-secretase inhibitors: application to subsite specificity. Rajamani R; Reynolds CH Bioorg Med Chem Lett; 2004 Oct; 14(19):4843-6. PubMed ID: 15341936 [TBL] [Abstract][Full Text] [Related]
12. [ANSA analysis. VI. Activation, inhibition and interaction of proteases in enzyme mixtures]. Cherkasov AV; Nedospasov VA; Iakhimovich AD; Nedospasov AA Biokhimiia; 1994 Oct; 59(10):1574-88. PubMed ID: 7819398 [TBL] [Abstract][Full Text] [Related]
13. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. Zuo Z; Luo X; Zhu W; Shen J; Shen X; Jiang H; Chen K Bioorg Med Chem; 2005 Mar; 13(6):2121-31. PubMed ID: 15727865 [TBL] [Abstract][Full Text] [Related]
14. Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease. Chen Y; Ma YT; Rando RR Biochemistry; 1996 Mar; 35(10):3227-37. PubMed ID: 8605158 [TBL] [Abstract][Full Text] [Related]
15. Chemical biology approaches reveal conserved features of a C-terminal processing PDZ protease. Weski J; Meltzer M; Spaan L; Mönig T; Oeljeklaus J; Hauske P; Vouilleme L; Volkmer R; Boisguerin P; Boyd D; Huber R; Kaiser M; Ehrmann M Chembiochem; 2012 Feb; 13(3):402-8. PubMed ID: 22267294 [TBL] [Abstract][Full Text] [Related]
16. An inhibitor of sequence-specific proteolysis that targets the substrate rather than the enzyme. Zhang Z; Ly T; Kodadek T Chem Biol; 2001 Apr; 8(4):391-7. PubMed ID: 11325594 [TBL] [Abstract][Full Text] [Related]
17. Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors. Blum A; Böttcher J; Sammet B; Luksch T; Heine A; Klebe G; Diederich WE Bioorg Med Chem; 2008 Sep; 16(18):8574-86. PubMed ID: 18760609 [TBL] [Abstract][Full Text] [Related]
18. Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. Ekonomiuk D; Su XC; Ozawa K; Bodenreider C; Lim SP; Otting G; Huang D; Caflisch A J Med Chem; 2009 Aug; 52(15):4860-8. PubMed ID: 19572550 [TBL] [Abstract][Full Text] [Related]
19. Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates. Gouvea IE; Izidoro MA; Judice WA; Cezari MH; Caliendo G; Santagada V; dos Santos CN; Queiroz MH; Juliano MA; Young PR; Fairlie DP; Juliano L Arch Biochem Biophys; 2007 Jan; 457(2):187-96. PubMed ID: 17184724 [TBL] [Abstract][Full Text] [Related]
20. "Reverse degradomics", monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products. Piccard H; Hu J; Fiten P; Proost P; Martens E; Van den Steen PE; Van Damme J; Opdenakker G Electrophoresis; 2009 Jul; 30(13):2366-77. PubMed ID: 19621364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]